JP2010534664A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010534664A5 JP2010534664A5 JP2010518314A JP2010518314A JP2010534664A5 JP 2010534664 A5 JP2010534664 A5 JP 2010534664A5 JP 2010518314 A JP2010518314 A JP 2010518314A JP 2010518314 A JP2010518314 A JP 2010518314A JP 2010534664 A5 JP2010534664 A5 JP 2010534664A5
- Authority
- JP
- Japan
- Prior art keywords
- fibrosis
- pharmaceutical formulation
- drug
- protein
- drugs
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 25
- 206010016654 Fibrosis Diseases 0.000 claims 16
- 230000004761 fibrosis Effects 0.000 claims 14
- 229940079593 drug Drugs 0.000 claims 11
- 239000003814 drug Substances 0.000 claims 11
- 102000013691 Interleukin-17 Human genes 0.000 claims 9
- 108050003558 Interleukin-17 Proteins 0.000 claims 9
- 102000004169 proteins and genes Human genes 0.000 claims 6
- 108090000623 proteins and genes Proteins 0.000 claims 6
- 239000005557 antagonist Substances 0.000 claims 4
- 208000019425 cirrhosis of liver Diseases 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 238000009472 formulation Methods 0.000 claims 3
- 238000007912 intraperitoneal administration Methods 0.000 claims 3
- 206010028537 myelofibrosis Diseases 0.000 claims 3
- 210000000056 organ Anatomy 0.000 claims 3
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 3
- 201000002793 renal fibrosis Diseases 0.000 claims 3
- 150000003384 small molecules Chemical group 0.000 claims 3
- 102000004127 Cytokines Human genes 0.000 claims 2
- 108090000695 Cytokines Proteins 0.000 claims 2
- 206010050207 Skin fibrosis Diseases 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 210000003403 autonomic nervous system Anatomy 0.000 claims 2
- 210000003169 central nervous system Anatomy 0.000 claims 2
- 208000003167 cholangitis Diseases 0.000 claims 2
- 230000007882 cirrhosis Effects 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- -1 cyclic amine Chemical class 0.000 claims 2
- 230000002526 effect on cardiovascular system Effects 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 229940127557 pharmaceutical product Drugs 0.000 claims 2
- 208000003476 primary myelofibrosis Diseases 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 230000002792 vascular Effects 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims 1
- 206010008609 Cholangitis sclerosing Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 206010048768 Dermatosis Diseases 0.000 claims 1
- 208000001708 Dupuytren contracture Diseases 0.000 claims 1
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- 206010019668 Hepatic fibrosis Diseases 0.000 claims 1
- 101000998146 Homo sapiens Interleukin-17A Proteins 0.000 claims 1
- 102000004554 Interleukin-17 Receptors Human genes 0.000 claims 1
- 108010017525 Interleukin-17 Receptors Proteins 0.000 claims 1
- 102100033461 Interleukin-17A Human genes 0.000 claims 1
- 208000002260 Keloid Diseases 0.000 claims 1
- 208000004362 Penile Induration Diseases 0.000 claims 1
- 208000020758 Peyronie disease Diseases 0.000 claims 1
- 206010036346 Posterior capsule opacification Diseases 0.000 claims 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims 1
- 208000017442 Retinal disease Diseases 0.000 claims 1
- 206010038923 Retinopathy Diseases 0.000 claims 1
- 201000009594 Systemic Scleroderma Diseases 0.000 claims 1
- 206010042953 Systemic sclerosis Diseases 0.000 claims 1
- 238000002399 angioplasty Methods 0.000 claims 1
- 229940051881 anilide analgesics and antipyretics Drugs 0.000 claims 1
- 150000003931 anilides Chemical class 0.000 claims 1
- 230000002924 anti-infective effect Effects 0.000 claims 1
- 229960005475 antiinfective agent Drugs 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 229940041181 antineoplastic drug Drugs 0.000 claims 1
- 229940054051 antipsychotic indole derivative Drugs 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 239000010839 body fluid Substances 0.000 claims 1
- 210000001124 body fluid Anatomy 0.000 claims 1
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 claims 1
- 230000009787 cardiac fibrosis Effects 0.000 claims 1
- 201000001981 dermatomyositis Diseases 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 239000003792 electrolyte Substances 0.000 claims 1
- 230000003176 fibrotic effect Effects 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 claims 1
- 102000037865 fusion proteins Human genes 0.000 claims 1
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 1
- 206010061989 glomerulosclerosis Diseases 0.000 claims 1
- 208000024908 graft versus host disease Diseases 0.000 claims 1
- 208000006454 hepatitis Diseases 0.000 claims 1
- 231100000283 hepatitis Toxicity 0.000 claims 1
- 150000002391 heterocyclic compounds Chemical class 0.000 claims 1
- 229940088597 hormone Drugs 0.000 claims 1
- 210000004276 hyalin Anatomy 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 229940121354 immunomodulator Drugs 0.000 claims 1
- 150000002475 indoles Chemical class 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 238000007914 intraventricular administration Methods 0.000 claims 1
- 210000001117 keloid Anatomy 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 235000016709 nutrition Nutrition 0.000 claims 1
- 208000030346 palmar fibromatosis Diseases 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 150000003233 pyrroles Chemical class 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 230000000241 respiratory effect Effects 0.000 claims 1
- 208000037803 restenosis Diseases 0.000 claims 1
- 201000000306 sarcoidosis Diseases 0.000 claims 1
- 201000004409 schistosomiasis Diseases 0.000 claims 1
- 208000010157 sclerosing cholangitis Diseases 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 208000017520 skin disease Diseases 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- 230000002227 vasoactive effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US95127007P | 2007-07-23 | 2007-07-23 | |
| US95541407P | 2007-08-13 | 2007-08-13 | |
| PCT/US2008/070588 WO2009015063A2 (en) | 2007-07-23 | 2008-07-21 | Methods and compositions for treating fibrosis related disorders using il-17 antagonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010534664A JP2010534664A (ja) | 2010-11-11 |
| JP2010534664A5 true JP2010534664A5 (enExample) | 2011-08-11 |
Family
ID=40282097
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010518314A Pending JP2010534664A (ja) | 2007-07-23 | 2008-07-21 | Ｉｌ−１７拮抗薬を用いた線維症関連疾患治療の方法及び組成物 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20110091378A1 (enExample) |
| EP (1) | EP2182943B1 (enExample) |
| JP (1) | JP2010534664A (enExample) |
| ES (1) | ES2614735T3 (enExample) |
| WO (1) | WO2009015063A2 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20170023209A (ko) | 2008-05-05 | 2017-03-02 | 노비뮨 에스 에이 | 항-ｉｌ-１７ａ／ｉｌ-１７ｆ 교차-반응성 항체 및 그의 사용 방법 |
| EP2413967A1 (en) * | 2009-04-01 | 2012-02-08 | F. Hoffmann-La Roche AG | Treatment of insulin-resistant disorders |
| CN102458437B (zh) | 2009-05-05 | 2015-06-10 | 诺维莫尼公司 | 抗il-17f抗体及其使用方法 |
| JP2011032170A (ja) * | 2009-07-29 | 2011-02-17 | Morinaga Milk Ind Co Ltd | ヒト細胞ｉｌ−１７産生抑制剤 |
| EP2485763A4 (en) * | 2009-10-10 | 2013-10-30 | Univ Leland Stanford Junior | CYTOKINE COMPOSITIONS OF THE IL-17 FAMILY AND ITS USES |
| AU2012204574B2 (en) * | 2011-01-04 | 2017-05-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of treating age-related macular degeneration |
| PL2686334T5 (pl) * | 2011-03-16 | 2020-10-19 | F.Hoffmann-La Roche Ag | Chromatografia jonowymienna o ulepszonej selektywności do rozdzielania monomerów, agregatów i fragmentów polipeptydowych przez modulację fazy ruchomej |
| WO2013116682A1 (en) | 2012-02-02 | 2013-08-08 | Ensemble Therapeutics Corporation | Macrocyclic compounds for modulating il-17 |
| AR103173A1 (es) | 2014-12-22 | 2017-04-19 | Novarits Ag | Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17 |
| CN109796534B (zh) * | 2017-11-16 | 2021-08-10 | 北京比洋生物技术有限公司 | 抗il-17抗体/tnfr ecd融合蛋白及其用途 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US5618920A (en) | 1985-11-01 | 1997-04-08 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
| US5576195A (en) | 1985-11-01 | 1996-11-19 | Xoma Corporation | Vectors with pectate lyase signal sequence |
| DE3751873T2 (de) | 1986-04-09 | 1997-02-13 | Genzyme Corp | Genetisch transformierte Tiere, die ein gewünschtes Protein in Milch absondern |
| US4704692A (en) | 1986-09-02 | 1987-11-03 | Ladner Robert C | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US4873316A (en) | 1987-06-23 | 1989-10-10 | Biogen, Inc. | Isolation of exogenous recombinant proteins from the milk of transgenic mammals |
| US4939666A (en) | 1987-09-02 | 1990-07-03 | Genex Corporation | Incremental macromolecule construction methods |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5750373A (en) | 1990-12-03 | 1998-05-12 | Genentech, Inc. | Enrichment method for variant proteins having altered binding properties, M13 phagemids, and growth hormone variants |
| JP3127158B2 (ja) | 1989-10-05 | 2001-01-22 | オプテイン，インコーポレイティド | 新規の遺伝子及びポリペチドの無細胞合成並びに単離 |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| ES2109945T3 (es) | 1990-06-01 | 1998-02-01 | Chiron Corp | Composiciones y procedimientos para identificar moleculas biologicamente activas. |
| US5723286A (en) | 1990-06-20 | 1998-03-03 | Affymax Technologies N.V. | Peptide library and screening systems |
| US5580734A (en) | 1990-07-13 | 1996-12-03 | Transkaryotic Therapies, Inc. | Method of producing a physical map contigous DNA sequences |
| WO1992005258A1 (en) | 1990-09-20 | 1992-04-02 | La Trobe University | Gene encoding barley enzyme |
| AU1435492A (en) | 1991-02-21 | 1992-09-15 | Gilead Sciences, Inc. | Aptamer specific for biomolecules and method of making |
| US5270170A (en) | 1991-10-16 | 1993-12-14 | Affymax Technologies N.V. | Peptide library and screening method |
| US5641670A (en) | 1991-11-05 | 1997-06-24 | Transkaryotic Therapies, Inc. | Protein production and protein delivery |
| US5733761A (en) | 1991-11-05 | 1998-03-31 | Transkaryotic Therapies, Inc. | Protein production and protein delivery |
| US5885793A (en) | 1991-12-02 | 1999-03-23 | Medical Research Council | Production of anti-self antibodies from antibody segment repertoires and displayed on phage |
| WO1994012520A1 (en) | 1992-11-20 | 1994-06-09 | Enzon, Inc. | Linker for linked fusion polypeptides |
| US5763733A (en) | 1994-10-13 | 1998-06-09 | Enzon, Inc. | Antigen-binding fusion proteins |
| US5549551A (en) | 1994-12-22 | 1996-08-27 | Advanced Cardiovascular Systems, Inc. | Adjustable length balloon catheter |
| EP0817847B2 (en) * | 1995-03-23 | 2009-09-09 | Immunex Corporation | Il-17 receptor |
| US5656730A (en) | 1995-04-07 | 1997-08-12 | Enzon, Inc. | Stabilized monomeric protein compositions |
| DE69830065T2 (de) | 1997-09-16 | 2006-01-19 | Egea Biosciences, LLC, San Diego | Methoden zur kompletten chemischen synthese und zusammensetzung von genen und genomen |
| US6670127B2 (en) | 1997-09-16 | 2003-12-30 | Egea Biosciences, Inc. | Method for assembly of a polynucleotide encoding a target polypeptide |
| US20070160576A1 (en) * | 2001-06-05 | 2007-07-12 | Genentech, Inc. | IL-17A/F heterologous polypeptides and therapeutic uses thereof |
| US20070053877A1 (en) * | 2003-08-21 | 2007-03-08 | Intermune, Inc. | Methods of treating idiopathic pulmonary fibrosis |
| JP2008500338A (ja) * | 2004-05-25 | 2008-01-10 | イコス・コーポレイション | 造血細胞の異常増殖を治療及び／又は予防する方法 |
| EP1765865A2 (en) * | 2004-06-10 | 2007-03-28 | ZymoGenetics, Inc. | Soluble zcytor14, anti-zcytor14 antibodies and binding partners and methods of using in inflammation |
| GB0417487D0 (en) * | 2004-08-05 | 2004-09-08 | Novartis Ag | Organic compound |
| AU2006214473A1 (en) * | 2005-02-14 | 2006-08-24 | Wyeth | Interleukin-17F antibodies and other IL-17F signaling antagonists and uses therefor |
| GT200600148A (es) * | 2005-04-14 | 2006-11-22 | Metodos para el tratamiento y la prevencion de fibrosis | |
| CA2660463C (en) * | 2006-08-11 | 2013-07-16 | Schering Corporation | Antibodies to il-17a |
-
2008
- 2008-07-21 JP JP2010518314A patent/JP2010534664A/ja active Pending
- 2008-07-21 US US12/670,179 patent/US20110091378A1/en not_active Abandoned
- 2008-07-21 WO PCT/US2008/070588 patent/WO2009015063A2/en not_active Ceased
- 2008-07-21 EP EP08782121.1A patent/EP2182943B1/en active Active
- 2008-07-21 ES ES08782121.1T patent/ES2614735T3/es active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010534664A5 (enExample) | ||
| US12286432B2 (en) | Fluorinated tetrahydronaphthyridinyl nonanoic acid derivatives and uses thereof | |
| JP2005512522A5 (enExample) | ||
| US8993622B2 (en) | Antiviral compounds | |
| JP2007508011A5 (enExample) | ||
| TWI410410B (zh) | Phenylacetic acid compounds | |
| RU2010126063A (ru) | Производные 4-(2-амино-1-гидроксиэтил)фенола как агонисты в2 адренергического рецептора | |
| CN103420917B (zh) | 含稠环结构的苯甲酰胺类化合物及其作为抗肿瘤药物应用 | |
| RU2003131178A (ru) | Агонисты никотиновых рецепторов для лечения воспалительных заболеваний | |
| US20160031847A1 (en) | Guanidinobenzoic acid ester compound | |
| JP2011517548A5 (enExample) | ||
| JPWO2003097031A1 (ja) | メチリデンヒドラジド化合物を有効成分とする、肥満の予防又は改善剤 | |
| CN106458920B (zh) | 炔基吲唑衍生物及其用途 | |
| JP2010511598A5 (enExample) | ||
| Huang et al. | Structure Optimization of c-Jun N-terminal Kinase 1 Inhibitors for Treating Idiopathic Pulmonary Fibrosis | |
| CN102202664A (zh) | 包含毒蕈碱性受体拮抗剂和β2肾上腺素受体激动剂的药物产品 | |
| US20100076038A1 (en) | Therapeutic agent for urinary excretion disorder | |
| US20240115567A1 (en) | Small therapeutic molecules capable of inhibiting the catalytic activity of the main protease enzyme of sars-cov-2 | |
| JPWO2003042194A1 (ja) | カルボン酸誘導体化合物およびその化合物を有効成分として含有する薬剤 | |
| JPWO2007026737A1 (ja) | 関節リウマチの予防及び／又は治療法 | |
| JP2025539088A (ja) | 骨格筋機能を改善する方法 | |
| WO2025213190A1 (en) | Methods of treating a disease or condition associated with weight gain | |
| US20090131443A1 (en) | Method for prevention and/or treatment of rheumatoid arthritis | |
| HK40066388A (en) | Fluorinated derivatives of 3-(2-oxo-3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)imidazolidin-1-yl)propanoic acid and uses thereof | |
| HK1241361B (en) | Fluorinated derivatives of 3-(2-oxo-3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)imidazolidin-1-yl)propanoic acid and uses thereof |